AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05281614
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept is a fully humanized monoclonal antibody that targets TNFα.
Trial: NCT05281614
Drug: Vedolizumab
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab is a humanized monoclonal antibody that targets α4ß7 integrin.
Trial: NCT00931905
Drug: Homeopathic medication Plumbum metallicum
RxNorm normalized name: Urtica urens homeopathic preparation
DrugBank: Plum (DB10560)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
Trial: NCT05724602
Drug: Xevinapant
RxNorm normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of xevinapant + IMRT followed by 3 cycles of xevinapant as monotherapy
Trial: NCT05002946
Drug: Naltrexone Hydrochloride 50Mg Oral Tablet
RxNorm normalized name: Naltrexone Hydrochloride 50mg Oral tablet
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT05567731
Drug: ultrashort GnRHa
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the patients used the ultrashort protocols with GnRH agonist (GnRH-a, and recombinant Follicle-Stimulating Hormone for controlled ovarian hyperstimulation (COH). Form the second day of menstrual cycle, 0.1 mg/d GnRHa will be injected by subcutaneous injection for 3-4 d.~Gonadotropins will be added from the third day of menstrual cycle and the initial gonadotropin doses will be 225-300 IU/d. During the treatment, gonadotropin doses will be adjusted according to guided monitoring of follicle growth and measurement of serum estradiol (E2) levels of 10 000 units of human chorionic gonadotrophin (hCG) will be administered when 43 follicles will be 418 mm
Trial: NCT05567731
Drug: short GnRHa
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
DrugBank: Ragweed pollen extract (DB05368)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buserelin acetate 100 mg five times daily and FSH will be started on the 2nd day of the menstrual cycle as short application. The dose of gonadotropin hormone will be individualized according to the patient's age and previous stimulation history or response to stimulation. Cycles will be monitored by transvaginal ultrasonography and serum estradiol (E2) levels.~Follicular maturation will be completed by the administration of 10000 IU human chorionic gonadotrophin (hCG) when at least two follicles reached a diameter of \>18 mm. Thirty-five to thirty-six hours after human chorionic gonadotrophin (hCG) administration, ovum retrieval will be performed by transvaginal echo-guided ovarian puncture.
Trial: NCT04782778
Drug: Bupivacaine 0.25% Injectable Solution
RxNorm normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg Bupivacaine (0.25%)
Trial: NCT06178874
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: hyperglycemic control
Trial: NCT06178874
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: hyperglycemic control
Trial: NCT06178874
Drug: Insulin regular
RxNorm normalized name: insulin regular
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hyperglycemic control
Trial: NCT04448184
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.~Tranexamic Acid will start when Platelet count is less than 50 x 109/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously.
Trial: NCT04145674
Drug: D-methadone
RxNorm normalized name: D-methadone
DrugBank: Dextromethadone (DB15198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take one tablet of 25 mg d-methadone once daily at 6 pm over a period of 30 days
Trial: NCT06403878
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: neoadjuvant chemotherapy，2cycles.
Trial: NCT06403878
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: neoadjuvant chemotherapy，2cycles.
Trial: NCT06403878
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant immunotherapy，2cycles.
Trial: NCT00001065
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05837104
Drug: Magnesium vitamin B6
RxNorm normalized name: magnesium oxide / vitamin B6
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium citrate (100mg) and Pyridoxine hydrochloride (10mg) in tablet form, taken three times daily for four weeks.
Trial: NCT05162053
Drug: vicagrel Capsules
RxNorm normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration for 7 days under fasting
Trial: NCT05162053
Drug: Clopidogrel Tablets
RxNorm normalized name: Clopidogrel Tablets
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration for 7 days under fasting
Trial: NCT05407961
Drug: Dulaglutide
RxNorm normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered SC.
Trial: NCT06116253
Drug: Tc-99m Pentetate
RxNorm normalized name: TECHNETIUM (Tc 99m)
DrugBank: Technetium Tc-99m (DB14227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive radioisotope (99mTc-DTPA) injection (5 mCi) during 3-5 hour scanning session to estimate measured glomerular filtration rate (mGFR).
Trial: NCT06508359
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic or rescue phenylephrine for spinal anesthesia-induced hypotension
Trial: NCT06176508
Drug: HS-10374
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally QD for 16 weeks
Trial: NCT06176508
Drug: Tofacitinib 5Mg Tab,Oral
RxNorm normalized name: TOFACITINIB 5MG TAB,ORAL
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally BID for 16 weeks
Trial: NCT04943692
Drug: Metformin glycinate
RxNorm normalized name: Glycine
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1050 mg, tablets Administered orally, twice a day, for 12 months.
Trial: NCT04943692
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850 mg, tablets. Administered orally, twice a day, for 12 months.
Trial: NCT06107660
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive either liposomal bupivacaine as part of the ESPB .
Trial: NCT06107660
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is the control group comparator as this is standard of care at the investigator's institution.
Trial: NCT06233994
Drug: Donafenib Tosilate Tablets
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donafenib will be administered at a dose of 0.2 g by orally, Bis in die(Bid).
Trial: NCT04707534
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone
Trial: NCT04199819
Drug: entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with evidence of OBI, as characterized by any one positive biomarker (serum HBV DNA, serum HBV RNA, serum HBcrAg, intrahepatic HBV DNA, intrahepatic cccDNA) in either the donor or recipient, will be commenced on life-long oral nucleos(t)ide analog therapy as part of their routine antiviral prophylaxis.
Trial: NCT06267638
Drug: Ketamine group
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive intraoperative ketamine during total knee arthroplasty
Trial: NCT06536959
Drug: PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For AML patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 28 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~For MDS patients: PD-1 inhibitor was given at a dose of 200mg on day 21 of the treatment. Venetoclax was given at a dose of 400 mg/day for 14 days per cycle. Decitabine was given at a dose of 20 mg/m2/day for 5 days or azacytidine was given at a dose of 75 mg/m2/day for 7 days at the discretion of the treating physician.~The venetoclax starting dose is 100 mg on the first day, ramping up to 200 mg on the second day and finally 400 mg once daily. The steady daily dose (after ramp-up phase) should be reduced to 100 mg (coadministered with moderate CYP3A inhibitors or P-gp inhibitors) and 70 mg (coadministered with strong CYP3A4 inhibitors).
Trial: NCT04389411
Drug: Montelukast 10mg
RxNorm normalized name: montelukast 10 MG
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg oral Montelukast will be taken daily for 60 days
Trial: NCT05402995
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline irrigation
Trial: NCT06484777
Drug: SHR-9539 for injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-9539 for dose escalation/dose extension
Trial: NCT05545670
Drug: Allopurinol 300 MG
RxNorm normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a competitive xanthine oxidase inhibitor, reduces oxidative stress and attenuates bacterial translocation
Trial: NCT05287191
Drug: Magnesium sulfate and then Digoxin
RxNorm normalized name: Magnesium Sulfate
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast Atrial Fibrillation persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance \<60 ml/min measured by the Modification of diet in renal disease formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.
Trial: NCT05287191
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
Trial: NCT05368207
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
Trial: NCT06285539
Drug: Filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Filgotinib
Trial: NCT06531603
Drug: bupivacaine wound infilteration
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug was given at the end of surgery
Trial: NCT06531603
Drug: Bupivacaine plus dexmedetomidine wound infilteration
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug was given at the end of surgery
Trial: NCT05219669
Drug: Nalmefene Hydrochloride
RxNorm normalized name: Nalmefene Hydrochloride
DrugBank: Nalmefene (DB06230)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30 mg/mL solution
Trial: NCT05951712
Drug: Simethicone 150mg
RxNorm normalized name: Simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impact of simethicone on the mucosal visibility of stomach and duodenum
Trial: NCT00214084
Drug: Allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05676697
Drug: Linperlisib
RxNorm normalized name: Linperlisib
DrugBank: Linperlisib (DB17235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The phosphatidylinositol 3-kinase delta (PI3Kδ) signaling pathway plays a critical role in the activation, proliferation, and tissue homing of self-reactive B cells that contribute to autoimmune diseases. B cells play an essential role in immune system function and dysfunction (e.g., autoimmunity) by producing antibodies and by acting as antigen-presenting cells (APCs) for T cells. Signaling via PI3K controls many essential B cell functions and is therefore a promising target for preventing aberrant B cell activation.
Trial: NCT06414499
Drug: rhTNK-tPA
RxNorm normalized name: tPA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds.
Trial: NCT00228592
Drug: HepeX-B
DrugBank: XTL-001 (DB05405)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00228592
Drug: Hepatitis B Immune Globulin (HBIg)
RxNorm normalized name: Hepatitis B Immune Globulin
DrugBank: Hepatitis B immune globulin (DB05276)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05329740
Drug: Methylprednisolone Injection
RxNorm normalized name: methylprednisolone Injection
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All eligible patients randomised to the glucocorticoid group will receive intravenous Methylprednisolone for 3 days after surgery. The dosage is 2mg/kg/d on post-operative day 1, 1mg/kg/d on post-operative day 2, and 0.5mg/kg/d on post-operative day 3. The daily dosage will be administered with two injections (12h interval).
Trial: NCT05709821
Drug: IMM60
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
Trial: NCT05709821
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
Trial: NCT05378074
Drug: Maxipost
RxNorm normalized name: Maxipost
DrugBank: Flindokalner (DB16908)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min MaxiPost.
Trial: NCT06189092
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using electroporation to infuse bleomycin in the lesion
Trial: NCT03559660
Drug: Certolizumab Pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05388942
Drug: Nitrous oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhalation of NO usually used to help with ASD reduction but inhaled NO has safety and maintenance issues.
Trial: NCT05225259
Drug: LOXO-260
RxNorm normalized name: Loxoprofene
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT05856643
Drug: SZ011 CAR-NK
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8, 2.0×10\^8and 5.0×10\^8 cells. The infusion is given every 2 weeks.
Trial: NCT01918514
Drug: Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain
RxNorm normalized name: magnesium sulfate Granules for Oral Solution
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05098353
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25-75 mg per day for 6 weeks
Trial: NCT00000833
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000833
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00175266
Drug: alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00175266
Drug: infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04949269
Drug: Deucravacitinib
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04949269
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04570293
Drug: 5% lidocaine medicated plaster
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The 5% lidocaine medicated plaster is measuring 10 cm x 14 cm contains 700 mg lidocaine (5% w/w) For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
Trial: NCT04932291
Drug: vafidemstat
RxNorm normalized name: Vafidemstat
DrugBank: Vafidemstat (DB16446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2mg capsule
Trial: NCT05623111
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo containing trace amounts of human albumin and sucrose, diluted with 5ml of sterile saline.
Trial: NCT06013436
Drug: Autologous serum tears combined with 0.05% cyclosporin eye drop
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients administrated autologous serum tears twelve times daily（per hour） and 0.05% cyclosporin eye drop twice times daily in each eye for 12 weeks.
Trial: NCT05301205
Drug: oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will be received oral gabapentin capsule 2 HOURS pre-operatively.
Trial: NCT04512638
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.
Trial: NCT05653284
Drug: AK130
RxNorm normalized name: Azelastine hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion, specified dose on specified days.
Trial: NCT06498869
Drug: Ketamine Hcl 50Mg/Ml Inj
RxNorm normalized name: KETAMINE HCL 50MG/ML INJ
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will be administered ketamine (0.25-0.50 mg/kg)
Trial: NCT06196814
Drug: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy.